Peptide · Fact sheet
Survodutide
Also known as BI 456906
Survodutide is not FDA approved. Phase 2 and Phase 3 trials have reported weight loss, reduced liver fat, and MASH-resolution signals, while fibrosis outcomes, longer-term benefits, safety, and regulatory decisions remain under study.
What is Survodutide?
Survodutide is a manufactured peptide that activates both the glucagon and GLP-1 receptors.
The dual design aims to combine appetite and glucose effects with glucagon-related energy and liver biology, but mechanistic breadth can also create tradeoffs.
Benefits & claims
It is among the most advanced dual glucagon/GLP-1 candidates for obesity and metabolic liver disease.
Phase 3 liver-fat results strengthen the human evidence without turning an investigational program into an approved medicine.
What the evidence supports
- A Phase 2 obesity trial reported substantial average weight reduction compared with placebo.
- MASH and MASLD trials reported favorable resolution or liver-fat endpoints, while fibrosis and long-term clinical outcomes require further evidence.
Research areas
- Obesity
- Metabolic dysfunction-associated steatohepatitis
- Liver fat and fibrosis
- Type 2 diabetes
- Chronic weight management
- MASH and MASLD
- Obesity with or without type 2 diabetes
Dosage & frequency
Human study contextSurvodutide is an investigational GLP-1/glucagon agonist. Study escalation schedules do not establish an approved maintenance dose.
Phase 2 obesity dose-finding trial
Adults age 18–75 with BMI at least 27, without diabetes
- Amount
- Target groups 0.6, 2.4, 3.6 or 4.8 mg
- Frequency
- Once weekly for 46 weeks
- Route studied or labeled
- Subcutaneous
The study included twenty weeks of escalation; target amounts are not initial treatment amounts.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Evidence in obesity and MASH comes from distinct study populations and endpoints.
Interactions & precautions
- Investigational dual-agonist trial safety does not establish compatibility with other incretin treatments or arbitrary combinations.
What is still unresolved
- Final indication, regimen, tolerability, and long-term clinical outcomes remain unresolved.
Side effects & risks
- Gastrointestinal adverse effects were the most frequent treatment-emergent problems in trials.
- Discontinuation and incomplete exposure complicate estimates of real-world benefit.
- Long-term glucagon-receptor effects and uncommon harms remain under study.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceRandomized Phase 2 studies and a Phase 3 MASLD study report meaningful weight and liver-fat effects. Those endpoints do not yet establish broad liver-outcome, cardiovascular, or long-term clinical benefit.
Studies
Controlled human study of body-weight efficacy, tolerability, and adverse events.
Biopsy-based MASH and fibrosis study with condition-specific endpoints.
Phase 3 liver-fat and body-weight trial with limited duration and geography.
Official Phase 3 obesity-study record and endpoint definitions.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Appetite: reported experiences
Little weight loss despite reduced hunger
A self-described blinded-trial participant reported slow weight loss, reduced hunger, headaches, constipation and nausea-like symptoms.
Amount, frequency, route and duration could not be confirmed for this account.
Treatment assignment was unknown. Diet and walking also changed, so neither symptoms nor weight change can be attributed to survodutide.
Read the original accountLess food preoccupation, with occasional diarrhea
Another trial commenter described early weight loss, less preoccupation with food, more energy and two diarrhea episodes.
Reported use in this account
- Product
- Blinded survodutide-study treatment; active drug or placebo not confirmed
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About three weeks before the fourth reported dose
The author explicitly linked some improvements to changed diet and exercise and did not know whether they received placebo.
Read the original accountWeight: reported experiences
Little weight loss despite reduced hunger
A self-described blinded-trial participant reported slow weight loss, reduced hunger, headaches, constipation and nausea-like symptoms.
Amount, frequency, route and duration could not be confirmed for this account.
Treatment assignment was unknown. Diet and walking also changed, so neither symptoms nor weight change can be attributed to survodutide.
Read the original accountLess food preoccupation, with occasional diarrhea
Another trial commenter described early weight loss, less preoccupation with food, more energy and two diarrhea episodes.
Reported use in this account
- Product
- Blinded survodutide-study treatment; active drug or placebo not confirmed
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About three weeks before the fourth reported dose
The author explicitly linked some improvements to changed diet and exercise and did not know whether they received placebo.
Read the original accountWeight loss followed by a plateau and burdensome vomiting
A commenter described weight loss followed by several months without further loss, and repeated vomiting that led them to leave the study.
Reported use in this account
- Product
- Survodutide-study treatment; allocation not stated
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Enrollment, treatment assignment and weight history were not independently verified.
Read the original accountGradual weight loss with nausea, aches and a long nap
A trial participant described about ten pounds of weight loss but stronger nausea, aches and tiredness after the first injection identified to them as 4.8 mg.
Reported use in this account
- Product
- Survodutide-study treatment; blinded allocation not confirmed
- Amount
- 4.8 mg as described by the participant
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Other exposures described: Ondansetron for nausea
The person believed they were in a higher-dose group, but the blinded study allocation is not confirmed. Back problems, reduced activity and eating changes complicate interpretation; schedule and total exposure duration are unstated.
Read the original trial commentEnergy: reported experiences
Less food preoccupation, with occasional diarrhea
Another trial commenter described early weight loss, less preoccupation with food, more energy and two diarrhea episodes.
Reported use in this account
- Product
- Blinded survodutide-study treatment; active drug or placebo not confirmed
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About three weeks before the fourth reported dose
The author explicitly linked some improvements to changed diet and exercise and did not know whether they received placebo.
Read the original accountGradual weight loss with nausea, aches and a long nap
A trial participant described about ten pounds of weight loss but stronger nausea, aches and tiredness after the first injection identified to them as 4.8 mg.
Reported use in this account
- Product
- Survodutide-study treatment; blinded allocation not confirmed
- Amount
- 4.8 mg as described by the participant
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Other exposures described: Ondansetron for nausea
The person believed they were in a higher-dose group, but the blinded study allocation is not confirmed. Back problems, reduced activity and eating changes complicate interpretation; schedule and total exposure duration are unstated.
Read the original trial commentPain: reported experiences
Gradual weight loss with nausea, aches and a long nap
A trial participant described about ten pounds of weight loss but stronger nausea, aches and tiredness after the first injection identified to them as 4.8 mg.
Reported use in this account
- Product
- Survodutide-study treatment; blinded allocation not confirmed
- Amount
- 4.8 mg as described by the participant
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Other exposures described: Ondansetron for nausea
The person believed they were in a higher-dose group, but the blinded study allocation is not confirmed. Back problems, reduced activity and eating changes complicate interpretation; schedule and total exposure duration are unstated.
Read the original trial commentDigestion: reported experiences
Little weight loss despite reduced hunger
A self-described blinded-trial participant reported slow weight loss, reduced hunger, headaches, constipation and nausea-like symptoms.
Amount, frequency, route and duration could not be confirmed for this account.
Treatment assignment was unknown. Diet and walking also changed, so neither symptoms nor weight change can be attributed to survodutide.
Read the original accountLess food preoccupation, with occasional diarrhea
Another trial commenter described early weight loss, less preoccupation with food, more energy and two diarrhea episodes.
Reported use in this account
- Product
- Blinded survodutide-study treatment; active drug or placebo not confirmed
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About three weeks before the fourth reported dose
The author explicitly linked some improvements to changed diet and exercise and did not know whether they received placebo.
Read the original accountWeight loss followed by a plateau and burdensome vomiting
A commenter described weight loss followed by several months without further loss, and repeated vomiting that led them to leave the study.
Reported use in this account
- Product
- Survodutide-study treatment; allocation not stated
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Enrollment, treatment assignment and weight history were not independently verified.
Read the original accountGradual weight loss with nausea, aches and a long nap
A trial participant described about ten pounds of weight loss but stronger nausea, aches and tiredness after the first injection identified to them as 4.8 mg.
Reported use in this account
- Product
- Survodutide-study treatment; blinded allocation not confirmed
- Amount
- 4.8 mg as described by the participant
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Not specified clearly
Other exposures described: Ondansetron for nausea
The person believed they were in a higher-dose group, but the blinded study allocation is not confirmed. Back problems, reduced activity and eating changes complicate interpretation; schedule and total exposure duration are unstated.
Read the original trial commentHeadache: reported experiences
Little weight loss despite reduced hunger
A self-described blinded-trial participant reported slow weight loss, reduced hunger, headaches, constipation and nausea-like symptoms.
Amount, frequency, route and duration could not be confirmed for this account.
Treatment assignment was unknown. Diet and walking also changed, so neither symptoms nor weight change can be attributed to survodutide.
Read the original accountApproval status
Survodutide remains investigational in the United States and is being evaluated in Phase 3 obesity and metabolic liver-disease programs.
Late-stage obesity and liver-disease research
Survodutide has Phase 3 trial evidence and registry records, but it remains investigational until an FDA review supports approval for a defined use.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether liver-fat and MASH-resolution changes translate into fewer liver complications
- Long-term cardiovascular, gallbladder, pancreatic, and metabolic outcomes
- Durability of weight and liver effects
- Whether the benefit-risk profile will support FDA approval
Summary
Survodutide remains investigational despite favorable metabolic and liver findings. Approval and longer-term clinical outcomes remain unresolved.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRandomized Phase 2 obesity trial
Controlled human study of body-weight efficacy, tolerability, and adverse events.
- pubmedRandomized Phase 2 MASH trial
Biopsy-based MASH and fibrosis study with condition-specific endpoints.
- pubmedSYNCHRONIZE-MASLD Phase 3 trial
Phase 3 liver-fat and body-weight trial with limited duration and geography.
- clinical trialsClinicalTrials.gov: SYNCHRONIZE-1
Official Phase 3 obesity-study record and endpoint definitions.